Investor Presentation - First Six Months of 2021
61
Investor presentation
First six months of 2021
Novo NordiskⓇ
In STEP 4, 41.2% of patients treated with semaglutide reached ≥20%
weight loss and reported improved quality of life versus placebo
Categorical weight loss
Sema 2.4 mg showed a statistically significant treatment
difference versus placebo in the SF-36 patient reported outcome
ETD [95% CI]
2.46 [1.59 3.32] *
1.44 [0.42 2.47] *
2.23 [-0.06 4.53]
1.86 [0.733.00] *
Proportion of patients
SF-36 scores
100%
90.5%
Sema 2.4 mg
Placebo
Physical functioning
80.8%
80%
65.5%
60%
50.0%
41.2%
40%
20%
0%
≥5%
≥10%
≥15%
≥20%
Weight loss
LL
20.9%
9.8%
5.1%
Physical component summary
Mental component summary
Role-physical
Bodily pain
General health
Vitality
Social functioning
Role-emotional
Mental health
Favours placebo Favours semaglutide
-1012
3 4 5 6 7 8
Descriptive statistics only. Based on the on-treatment data, i.e. data for people that are on-treatment at week 68
Sema: semaglutide
4.31 [1.617.02] *
2.41 [0.07 4.76] *
1.64 [0.52 2.76] *
2.93 [1.80 4.06]
1.68 [0.64 2.72] *
3.44 [2.28 4.60] *
*
* statistically significant; p-values other than physical functioning were not controlled for multiplicity
CI: confidence interval, ETD: estimated treatment difference, Sema: semaglutide, SF-36: Short Form (36) Health SurveyView entire presentation